Program
Radiosensitizer VS-101
Also written as “VS-101”, “VS101 Insert Dose A” and “VS101 Insert Dose B”.
Its studies are mostly in Neoplasms, Squamous Cell · Glaucoma, Open-Angle, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ViSci | 10 open or running | phase 2since Apr 30, 2014 | Apr 30, 2014 | none ahead |
| VSPharmTech | 11 open or running | phase 2since Apr 16, 2025 | Apr 16, 2025 | Dec 2027phase 2 · NCT06959082 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2014First study: phase 2 study in Glaucoma, Open-AngleNew to ViSciViSci · NCT02129673 · 77 enrolled · United States
- Apr 16, 2025VSPharmTech’s first study: phase 2 study in Head and Neck Cancer Squamous Cell CarcinomaNew to VSPharmTechVSPharmTech · NCT06959082 · 30 planned · United States
Ahead
- Dec 2027Primary completion: phase 2 study in Head and Neck Cancer Squamous Cell CarcinomaVSPharmTech · NCT06959082
TargetBeta
“An orally bioavailable inhibitor of survivin and generator of reactive oxygen species (ROS), ”NCIt, by rule
Other programs on ROS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| taletrectinibrule | Nuvation Bio | phase 3 | 11 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| Fudotinibrule | guangzhou-joyo-pharma-co-ltd | phase 3 | 3 |
| Cross-over to JYP0322rule | guangzhou-joyo-pharma-co-ltd | phase 3 | 1 |
| ROS1/NTRK Inhibitor ANS03rule | avistone-biotechnology-co-ltd | phase 1 | 1 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06959082Head and Neck Cancer Squamous Cell Carcinoma · United States | 2 | Recruiting | VSPharmTech | Dec 2027 | 30 |
| NCT02129673Glaucoma, Open-Angle · United States | 2 | Completed | ViSci | May 2017 | 77 |
How it is read
Names in the registry
- “VS-101”, 1 entry
- “VS101 Insert Dose A”, 1 entry
- “VS101 Insert Dose B”, 1 entry
- “VS101 Insert Dose C”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, Squamous Cell, 1 study
- Glaucoma, Open-Angle, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.